Reported Standalone quarterly numbers for Sun Pharma Advanced Research Company are:
Net Sales at Rs 28.46 crore in June 2022 up 29.42% from Rs. 21.99 crore in June 2021.
Story continues below Advertisement
Quarterly Net Loss at Rs. 82.35 crore in June 2022 down 34.19% from Rs. 61.37 crore in June 2021.
EBITDA stands negative at Rs. 78.02 crore in June 2022 down 45.91% from Rs. 53.47 crore in June 2021.
Sun Pharma Adv shares closed at 223.55 on August 05, 2022 (NSE) and has given -30.61% returns over the last 6 months and -21.33% over the last 12 months.
Story continues below Advertisement
| Sun Pharma Advanced Research Company | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'22 | Mar'22 | Jun'21 | | Net Sales/Income from operations | 28.46 | 25.24 | 21.99 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 28.46 | 25.24 | 21.99 | | EXPENDITURE | | Consumption of Raw Materials | 5.70 | 6.38 | 2.87 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 25.05 | 23.08 | 25.52 | | Depreciation | 2.70 | 2.51 | 2.53 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 75.91 | 62.32 | 47.87 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -80.90 | -69.05 | -56.80 | | Other Income | 0.18 | 0.22 | 0.80 | | P/L Before Int., Excpt. Items & Tax | -80.72 | -68.83 | -56.00 | | Interest | 1.63 | 2.22 | 5.37 | | P/L Before Exceptional Items & Tax | -82.35 | -71.05 | -61.37 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -82.35 | -71.05 | -61.37 | | Tax | -- | -- | -- | | P/L After Tax from Ordinary Activities | -82.35 | -71.05 | -61.37 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -82.35 | -71.05 | -61.37 | | Equity Share Capital | 27.19 | 27.19 | 26.21 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -3.03 | -2.69 | -2.34 | | Diluted EPS | -3.03 | -2.69 | -2.34 | | EPS After Extra Ordinary | | Basic EPS | -3.03 | -2.69 | -2.34 | | Diluted EPS | -3.03 | -2.69 | -2.34 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
